This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.(1) Intramuscluar prime boost vaccination with the Ad5 HIV-1 gag vaccine will be generally safe and well-tolerated. (2) Four weeks after the boost vaccination with the Ad5 HIV-1 gag vaccine, at least one of the four vaccine dose groups will exhibit an immune response that is better than the placebo, based on the unfractionated gag-specific IFN-y ELISPOT assay.
Showing the most recent 10 out of 515 publications